Announced Wed, 5 Aug, 2026 · 13:55 IST

Q1 FY27 Results: Standalone Loss, Consolidated Profit Up; Plant Update

Revenue DeclinePat Growth 25pctPat NegativeResults View source PDF Explain this filing

BALAXI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.7%Reaction day

₹24.00

prior close

₹24.99

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%+0.4% vs market

On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.4

10m

-1.3

15m

-0.8

30m

-3.3

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

+1.7+1.3+0.4

Next day

+0.9+1.6-0.8

+2.2+1.7+0.5

+0.5+1.6-1.2

-1.2+1.5-2.7

+0.0+1.8-1.8

+0.0+2.1-2.0

15d

-5.8+3.2-9.0

+0.1+3.7-3.6

-4.8+1.1-5.9

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1 FY27: Standalone revenue fell to Rs 15.58 cr from Rs 16.71 cr YoY, slipping to a loss of Rs 1.25 cr vs Rs 19.5 lakh profit. Consolidated revenue grew to Rs 80.68 cr from Rs 70.74 cr; net profit up to Rs 1.30 cr from Rs 29 lakh. Board noted commercial production started at new Jadcherla formulation plant with 2 products, 29 more approved. WHO-GMP audit done, CAPA submitted.

Likely market impact

Standalone weak but consolidated strong; new plant adds long-term growth optionality